Emergent Biosolut Stock Return On Equity
| ER4 Stock | EUR 5.25 0.08 1.50% |
EMERGENT BIOSOLUT fundamentals help investors to digest information that contributes to EMERGENT BIOSOLUT's financial success or failures. It also enables traders to predict the movement of EMERGENT Stock. The fundamental analysis module provides a way to measure EMERGENT BIOSOLUT's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EMERGENT BIOSOLUT stock.
EMERGENT |
EMERGENT BIOSOLUT Company Return On Equity Analysis
EMERGENT BIOSOLUT's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, EMERGENT BIOSOLUT has a Return On Equity of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Other (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
EMERGENT Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EMERGENT BIOSOLUT's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of EMERGENT BIOSOLUT could also be used in its relative valuation, which is a method of valuing EMERGENT BIOSOLUT by comparing valuation metrics of similar companies.EMERGENT BIOSOLUT is currently under evaluation in return on equity category among its peers.
EMERGENT Fundamentals
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B | |||
| Total Asset | 3.17 B | |||
| Z Score | 2.4 | |||
| Net Asset | 3.17 B |
About EMERGENT BIOSOLUT Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EMERGENT BIOSOLUT's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EMERGENT BIOSOLUT using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EMERGENT BIOSOLUT based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.